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Abstract
Background: Antibody fragments are molecules widely used for diagnosis and therapy. A large
amount of protein is frequently required for such applications. New approaches using folding
reporter enzymes have recently been proposed to increase soluble expression of foreign proteins
in Escherichia coli. To date, these methods have only been used to screen for proteins with better
folding properties but have never been used to select from a large library of mutants. In this paper
we apply one of these methods to select mutations that increase the soluble expression of two
antibody fragments in the cytoplasm of E. coli.
Results: We used the β-galactosidase α-complementation system to monitor and evolve two
antibody fragments for high expression levels in E. coli cytoplasm. After four rounds of mutagenesis
and selection from large library repertoires (>107 clones), clones exhibiting high levels of β-
galactosidase activity were isolated. These clones expressed a higher amount of soluble fusion
protein than the wild type in the cytoplasm, particularly in a strain deficient in the cytoplasmic Lon
protease. The increase in the soluble expression level of the unfused scFv was, however, much less
pronounced, and the unfused proteins proved to be more aggregation prone than the wild type. In
addition, the soluble expression levels were not correlated with the β-galactosidase activity present
in the cells.
Conclusion: This is the first report of a selection for soluble protein expression using a fusion
reporter method. Contrary to anticipated results, high enzymatic activity did not correlate with the
soluble protein expression level. This was presumably due to free α-peptide released from the
protein fusion by the host proteases. This means that the α-complementation assay does not sense
the fusion expression level, as hypothesized, but rather the amount of free released α-peptide.
Thus, the system does not select, in our case, for higher soluble protein expression level but rather
for higher protease susceptibility of the fusion protein.
Background
Because of their high affinity and specificity against their
antigen, antibody molecules and their fragments have
many applications in research, diagnosis and therapy [1].
E. coli is a widely used organism for the production of pro-
teins, including antibody fragments such as Fab or single
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chain variable domains (scFv). Active scFv can be
obtained by targeting the protein to E. coli periplasm,
where the two disulfide bonds needed for protein folding
and stability [2-4] can form. The amount of scFv produced
is however usually low, in the range of 0.1–1 mg l-1 of cul-
ture at an optical density (OD600) of 1, even if expression
levels of 10 mg l-1 have sometimes been reported [5].
An alternative strategy to produce antibody fragments in
E. coli has been to maintain the scFv in the cytoplasm by
removing its signal sequence. Under those conditions,
scFv might be expressed at very high levels, albeit in an
insoluble and inactive conformation. Even if highly effi-
cient in vitro refolding procedures have been developed
for scFv and Fab [6,7], it would be more suitable to
directly recover soluble active protein from the cytoplasm
of the cell. This has been partially accomplished by mod-
ifying the cytoplasmic oxido-redox environment by
mutating components of the thioredoxin and glutare-
doxin pathways [8], resulting in the accumulation of sol-
uble intra-cytoplasmic oxidized antibody fragments [9-
11]. The soluble expression levels reported, however, are
not higher than those obtained in the periplasm of the
cell. Another interest in expressing soluble active scFv in
the reducing environment of the cytoplasm is that the
expression of scFv molecules inside the cell can be used to
block viral replication and to inhibit oncogene products
[12-15]. The use of so-called intrabodies opens many
interesting possibilities in gene therapy [16] and in the in
vivo study of protein function [17].
Several methods have been proposed in recent years to
increase the soluble expression levels of foreign proteins
expressed in E. coli cytoplasm [18]. Most of these methods
rely on fusion between the protein of interest and a
reporter enzyme. If the protein folds into a soluble confor-
mation, the fused enzyme will be active; but if the protein
ends up as an inclusion body, the fused enzyme will be
inactive, resulting in a null phenotype. Three reporter
enzymes have been used to date, the green fluorescent
protein (GFP [19]), the chloramphenicol acetyl trans-
ferase (CAT [20]) and the β-galactosidase (βgal [21]). In
the case of βgal, the whole enzyme was not fused to the
protein of interest but only a small N-terminal fragment
of about 50 aminoacids called the α-fragment [22]. The
inactive enzyme remainder was expressed in trans by the
bacteria (β-galactosidase ∆M15 protein), resulting in in
vivo complementation and a lactose+ (lac+) phenotype
[23]. The role of the α-fragment is to promote the
tetramerization of the inactive dimeric ∆M15 mutant
[24], resulting in βgal activation.
Using the GFP fusion method, Waldo and collaborators
[18,25,26] isolated several soluble variants of aggregating
proteins. However, since the method is based on a pheno-
typic screen, it is limited to the exploration of libraries of
about 105 clones and does not allow the isolation of
mutants from very large libraries. This is not the case for
the two other methods which should allow the selection
of very rare events by selecting for chloramphenicol resist-
ance or growth on lactose as the carbon source. To date,
there is, however, no report of protein evolution and
selection using these latter two methods even if the CAT
system has been used to pre-select libraries of hybrid pro-
teins to avoid stop codons and enrich in properly folded
molecules [27].
We previously showed that it is possible to evolve an scFv
molecule for very high expression levels in E. coli cyto-
plasm [4,28,29]. This evolved scFv is active in the cell and
its expression level is as high as 100 mg l-1 at an OD600 of
1. This was, however, a very rare event, and the selection
had to be conducted using large libraries of 107–108
mutants. The selection procedure used was restricted to
the properties of a particular antibody molecule able to
activate βgal mutants in vitro and in vivo. To extend this
result to other scFv molecules, we constructed fusions
between two scFv and the α-fragment of βgal to monitor
the soluble expression level in vivo. The lactose phenotype
of the strain was then used to select mutants with
improved lactose utilization and thus presumably
expressing scFv at a higher level in the bacterial cytoplasm.
Results
System design
In order to easily fuse scFv to the α-fragment of βgal, we
constructed the plasmid pPM170, derived from pUC119
and which contains a lac promoter followed by a NcoI and
a NotI site in which an scFv can be easily cloned in frame
with the α-fragment present in the pUC119 plasmid. The
α-fragment is separated from the protein by a linker con-
sisting of two tags (Fig. 1).
To verify that the system was indeed able to discriminate
soluble scFv expression levels in the cytoplasm, we used a
set of mutant scFv derived from the human scFv13 and
presenting a gradual increase in soluble expression [28].
The expression levels of these scFv have been previously
studied in E. coli cytoplasm using the tryptophan pro-
moter: The best mutant, 13R4, is expressed at about a 50
times higher level than the wild type scFv13 and the
expression levels increased gradually from scFv13 to
scFv13R4 (in the rank order 13 < 13R1 < 13R2 < 13R3 <
13R4). These scFv were cloned in pPM170 (plasmids
pPM173 to pPM173R4). Fig. 2A shows the phenotype on
MacConkey lactose plates of strain TG1 containing the
plasmids. As expected, the phenotype gradually increased
from lac- (white colonies) for pPM173 expressing the wild
type scFv13 to a strong lac+ phenotype when the plasmid
contained the best expressed mutant 173R4. TheMicrobial Cell Factories 2004, 3:16 http://www.microbialcellfactories.com/content/3/1/16
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Schematic view of plasmid pPM170 Figure 1
Schematic view of plasmid pPM170 Plasmid pPM170 allows the cloning of scFv genes between the NcoI and NotI sites 
under the control of the lactose promoter. The translated protein is fused at its C-terminal extremity to the α-fragment of 
βgal. A) Plasmid map with the main restriction sites; B) DNA and aminoacid sequences fused to the 3' end and the C-terminus 
of the cloned scFv. The scFv sequence is followed by two tags (in blue), the α-fragment of βgal (in green, aminoacids 6 to 59 of 
βgal) and a 30 aminoacid long peptide (in orange) originating from pBR322 plasmid and M13 gene IV sequence (see text). The 
sequences of the two sequenced spontaneous lac+ mutants, 173S1 and 173S2 (see text), are also shown.Microbial Cell Factories 2004, 3:16 http://www.microbialcellfactories.com/content/3/1/16
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Lactose phenotype correlates with the soluble expression levels Figure 2
Lactose phenotype correlates with the soluble expression levels Phenotype of strain TG1 transformed with the 
pPM170 plasmid containing a series of scFv with different soluble expression levels in E. coli cytoplasm. The scFv13, 13R1, 13R2, 
13R3 and 13R4 are described in [28]. T- and T+ are TG1 transformed with the pTrc99A and pUC119 plasmids, respectively. 
173S1 is a spontaneous lac+ mutant isolated from TG1(pPM173) (see text and Fig. 1). A) Lactose phenotype on MacConkey 
lactose plates. The ability of the cell to use lactose is proportional to the depth of the red coloration. B) βgal activity present in 
the cytoplasm of the cells measured using Miller's whole cell assay [30].Microbial Cell Factories 2004, 3:16 http://www.microbialcellfactories.com/content/3/1/16
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phenotype of this latter strain is comparable to the pheno-
type of the strain containing an unmodified pUC119 plas-
mid giving normal α-complementation (T+).
The level of α-complementation was further characterized
by measuring the βgal activity present in the cell using the
whole cell assay developed by Miller [30]. The result
shown in Fig. 2B demonstrated that the βgal activity in
TG1(pPM173) was close to background level and that the
activity increased gradually to 100% of the activity of the
positive α-complementation control. This clearly demon-
strated the correlation between the soluble cytoplasmic
expression levels of the scFv and the lactose phenotype of
the strain, opening the way to direct selection of mutant
proteins using this assay.
Spontaneous lactose plus mutants
When TG1(pPM173) was incubated 2 to 3 days at 37°C,
red papillae appeared on the MacConkey plates. These
clones were isolated and showed a stable lac+ phenotype,
comparable to a wild type lac+ strain. One of the clones,
173S1, had even a higher βgal activity in its cytoplasm
than the pUC119 rescued ∆M15 strain (Fig. 2B). The
increase in βgal activity was shown to be linked to the
plasmid by transforming TG1 with the plasmid extracted
from TG1(pPM173S1). To determine if the mutation was
located in the scFv, we excised the gene from the plasmid
using the NcoI and NotI sites and cloned it back in
pPM170. The resulting clone was lac- (data not shown),
demonstrating that the mutation responsible for the lac+
phenotype was associated with the plasmid but not with
the scFv.
To understand the origin of this phenotypic change, we
sequenced the α-fragment of two of the clones, 173S1 and
173S2. Both contained a mutation in the α-fragment of
the βgal, resulting in a stop codon (Fig. 1) at positions 49
and 50. It should be noted that the stop codon of 173S1
is an amber codon which is partially suppressed in TG1
and replaced by a Gln, resulting in this case in two differ-
ent fusions, one stopping at position 49 of the βgal and
the second with a complete α-fragment, showing that the
mutant is dominant over the wild type.
Analysis of the sequence of the α-fragment present in
pUC119 (and pPM170), showed that a 30 aminoacid
long peptide of unknown origin was fused to the C-termi-
nal extremity of the α-fragment (Fig. 1). This peptide (or
part of it) was present in all the pUC derived plasmids.
Sequence analysis showed that this peptide originated
from a fusion between a DNA sequence present in
pBR322 plasmid between the NdeI and EarI sites (nucle-
otides 2297 to 2351 of pBR322; LMR...HRI translated
sequence) and the 3' end of M13 gene IV (nucleotides
5470 to 5511 of M13; RQS...AAH translated sequence).
The pBR322 sequence, located between the rop gene and
the origin of replication, is not normally translated, and
the M13 gene IV sequence is read out of frame.
Two explanations could account for the stronger lactose
phenotype of the 173S1 clone when the extra peptide was
removed from the fusion. Either this peptide impaired the
α-complementation, or the presence of this peptide
changed the expression level of the scFv. To test these
hypotheses, we expressed the scFv13 and scFv13R4 clones
as fusion proteins either to the α-peptide followed by the
30 aminoacid long peptide (173 and 173R4) or to the
shorter α-peptide of clone 173S1 (173S1 and 173S1-R4).
As shown in Figure 3B, the expression level of the fusions
was much higher with the shorter α-peptide. This demon-
strated that the additional C-terminal peptide lowered the
protein expression level, presumably by directing the scFv
to the cell degradation machinery since both the insoluble
and the soluble expression levels where decreased. In all
cases, the fusion proteins were degraded, and a band
migrating to about 30 kDa was visible. This band may cor-
respond to an unfused scFv liberated by host proteases.
However, despite a strong increase in the expression level
of 173S1-R4 versus 173S1, the lactose phenotypes of both
clones expressed in strain TG1 were comparable (Fig. 3A).
This showed that the link between the lactose phenotype
and the intracellular expression levels of scFv13 shown in
Figure 2 was due to the presence of the 30 aminoacid long
peptide. Indeed, in the case of 173S1, the α-complemen-
tation detection system is saturated and the strong lactose
phenotype of strain TG1(173S1) would not allow the
selection of evolved mutants with a stronger phenotype.
This prompted us to retain this foreign 30 aminoacid long
peptide for selection and to adapt the procedure to avoid
the selection of spontaneous stop codons.
Molecular evolution
The outline of the selection procedure is shown in Figure
4A. We first introduced random mutations at a low rate
(0.2%) in the scFv gene using error-prone PCR. The muta-
genized gene was cloned in the pPM170 vector and trans-
formed in TG1 bacteria to give a library of at least 107
clones. Transformed bacteria were plated on selective
medium containing lactose as the unique carbon source,
allowing the selection of lac+ clones. After 1 to 3 days at
37°C, about 10 to 100 clones able to grow under these
conditions were cultured in 96-well microtiter plates, then
pooled before plasmid extraction. To avoid the isolation
of spontaneous lac+ mutations in the α-fragment (see
above), the NcoI-NotI fragment containing the scFv gene
was excised from the pooled plasmids and cloned back in
pPM170. After transformation in TG1, a small number of
clones (typically 100 to 1000) was screened on MacCo-
nkey lactose agar plates and the deepest red colonies fur-Microbial Cell Factories 2004, 3:16 http://www.microbialcellfactories.com/content/3/1/16
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Effect of the 30 aminoacid long C-terminal peptide on scFv expression level Figure 3
Effect of the 30 aminoacid long C-terminal peptide on scFv expression level scFv13 and scFv13R4 were cloned 
either in pPM170 (173 and 173R4) or in pPM173S1 (173S1 and 173S1-R4), and expressed in strain TG1. A) Phenotype of the 
strains on MacConkey lactose plates after 24 h at 37°C. B) Soluble and insoluble extracts of the four strains were analyzed by 
Coomassie blue staining (top) or by western blot (bottom) using the 9E10 anti-c-myc monoclonal antibody followed by an anti-
mouse HRP-conjugated antibody and detected with a commercial kit (Pierce Supersignal West Pico kit #14079). The arrows 
show the position of the fusions (38 kDa for 173 and 173R4; 34 kDa for 173S1 and 173S1-R4) and the unfused scFv (28 kDa).
Outline of the selection procedure Figure 4
Outline of the selection procedure A) Outline of the steps followed during the selection procedure; B) Size of the libraries 
generated and number of clones isolated after each round of selection and used as a pool for the next round.Microbial Cell Factories 2004, 3:16 http://www.microbialcellfactories.com/content/3/1/16
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ther analyzed. This last screen was done after a 24-h
incubation at 37°C in order to avoid the selection of
spontaneous red colonies that appeared after about 2 to 3
days.
Two scFv were chosen as models. We first used a human-
ized D1.3 anti-lysozyme antibody, HuLys11 [31]. This
antibody has been extensively studied and its structure
solved by X-ray crystallography. The second scFv was
derived from the mouse monoclonal antibody 225.28S
and recognizes the high molecular weight melanoma-
associated antigen [32]. As such, this antibody might have
potential applications in the treatment of that type of
cancer.
Four rounds of mutagenesis and selection were done for
both scFv. The size of the libraries and the number of
clones isolated after each round are shown in Figure 4B.
The phenotype of the clones increased during the selec-
tion from an almost lac- to a clearly lac+ phenotype. This
is shown in Figure 5A for 225.28S scFv, where the best five
isolated clones (R4.1 to R4.5) exhibited a deeper red color
than the original clone (175), demonstrating a greater
ability to use lactose as a carbon source. In addition, the
phenotype was close to the phenotype obtained with the
pUC119 plasmid, that is, normal α-complementation.
The results obtained with HuLys11 were comparable, but
the colonies showed a weaker lactose phenotype (data not
shown).
All the isolated clones were different at the DNA and pro-
tein level. The mutants of scFv225.28S contained 8–14
nucleotide substitutions and 3–9 mutations in the protein
(see additional files 1 and 2, 22528Sdna.txt and
22528Saa.txt). In the case of HuLys11, the three isolated
mutants contained 4–5 nucleotide substitutions and 2–3
aminoacid mutations (see additional files 3 and 4,
HuLys11dna.txt and HuLys11aa.txt). The mutations did
not cluster together either in the DNA sequence nor in the
protein or in the structure of the scFv. In the case of
HuLys11, for which a high resolution structure is availa-
ble, three of the four isolated mutations are located in β-
strands and are solvent exposed (see additional file 4,
HuLys11aa.txt and Fig. 6).
To confirm the phenotype shown on the plates, βgal activ-
ity was measured using the assay described by Miller [30].
The assay relies on cell lysis by chloroform/SDS and as
such measures the amount of βgal activity present in the
whole cell. As shown in Figure 5B, the βgal activity present
in the mutants was about five to seven times higher than
in the strain expressing the wild type 225.28S scFv fused
to the α-fragment and five times lower than in the control
cells expressing the unfused α-fragment from the pUC119
Phenotype of the isolated mutants Figure 5
Phenotype of the isolated mutants After four rounds of mutagenesis and selection, the five best clones of scFv 225.28S 
were analyzed in strain TG1. pPM175 contains the wild type scFv and pPM175R4.1 to pPM175R4.5 the five isolated mutants. 
T+ and T- are the same as in Fig. 2. A) Phenotype of the strains on MacConkey lactose plates; B) βgal activity measured as in 
Figure 1. In addition to the Miller's whole cell assay (blue), we analyzed in B the βgal activity present in soluble extracts (red).Microbial Cell Factories 2004, 3:16 http://www.microbialcellfactories.com/content/3/1/16
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plasmid. In oder to confirm that this increase in βgal activ-
ity was localized in the soluble protein fraction, we meas-
ured the activity in soluble extracts of the cells prepared by
lysozyme treatment and centrifugation. The results were
comparable to those obtained with the whole cell assay
(Fig. 5B), demonstrating that indeed the increase in βgal
activity was due to an increase in α-complementation in
the soluble protein fraction.
Fused scFv-α characterization
To determine whether the expression levels of the mutant
scFv were higher than those of the wild type protein,
soluble and insoluble extracts were prepared and
analyzed (Fig. 7). No protein was detectable by western
blot in the case of the wild type scFv225.28S or mutants
R4.2 and R4.4, and only a faint band was visible in the sol-
uble extracts of the other clones (R4.1, R4.3 and R4.5. Fig.
7C &7D). This showed that indeed, as expected from the
βgal levels measured in Figure 5, some of the mutants
were expressed at a higher level in the cytoplasm than the
wild type but that most of the scFv was degraded by the
host proteases.
Location of isolated mutations in HuLys11 scFv structure Figure 6
Location of isolated mutations in HuLys11 scFv 
structure Schematic representation of the HuLys11 scFv 
(pdb 1BVK). The CDR loops are represented in blue. The 
side chain of three of the four isolated mutations (see addi-
tional file HuLys11aa.txt) are represented in red. The fourth 
mutation, located in the linker sequence, is not present in the 
structure.
Expression of scFv-α fusions in TG1 and TG1lon strains Figure 7
Expression of scFv-α fusions in TG1 and TG1lon strains SDS-PAGE of soluble (5 µl : A, C & F) and insoluble extracts (5 
µl ; B, D & G) of the five best clones of scFv 225.28S (A, B, C & D) and scFv HuLys11 (F & G) expressed in TG1 and TG1lon. 
Proteins were revealed either by Coomassie blue staining (A & B) or by western blot (C, D, F & G) using an HRP-coupled anti-
polyHistidine monoclonal antibody (Sigma A7058) and detected with a commercial detection kit (Pierce Supersignal West Pico 
kit #14079). In panel E, the same soluble extracts than in C were tested for βgal activity.Microbial Cell Factories 2004, 3:16 http://www.microbialcellfactories.com/content/3/1/16
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To test this hypothesis, we expressed the clones in a TG1
strain deficient in the cytoplasmic Lon protease. This pro-
tease has been shown to be involved in the degradation of
many recombinant proteins in E. coli [33]. When
expressed in such a strain, the wild type scFv225.28S was
detected in the soluble fraction, albeit at a very low level
(Fig. 7C), and no scFv was present in the insoluble frac-
tion. All the evolved scFv were expressed at a much higher
level than the wild type, mainly as soluble proteins (Fig.
7C &7D), showing that the scFv225.28S proteins were
predominantly degraded by the Lon protease in vivo. The
same type of result was obtained with scFv HuLys11 since
the wild type scFv was not detected in any of the extracts,
and the evolved scFv were detected in the soluble fraction
of the Lon deficient strain (Fig. 7F&7G). The Lon protease
is not the only protease present in the E. coli cytoplasm
[34] and in its absence some degradation of the fusion is
still present as shown by the additional band at about 30
kDa in Fig. 7C &7D. This molecular weight is consistent
with a degradation site located between the scFv and the
α-peptide and could be one of the sources of the free α-
peptide liberated in the cell cytoplasm (see below). It
should be noted that in the reported cases of the success-
ful isolation of soluble variants of aggregating proteins
using the GFP system [25,26], the authors used an E. coli
B strain, naturally deficient in the Lon protease [33,35].
The soluble extracts of scFv225.28S and its mutants were
tested for the presence of βgal activity (Fig. 7E). The results
obtained in strain TG1 were comparable, as expected, to
those obtained previously (Fig. 5). There is however no
clear correlation between the soluble expression level and
the βgal activity since clone R4.1, which is expressed at the
highest level, did not give a higher signal than the non-
detected clones, R4.2 and R4.4. In the Lon-deficient strain,
all the clones, including the wild type scFv225.28S, gave
the same signal despite the fact that the wild type scFv was
only barely detectable in the extract. These results showed
that there was no correlation between the soluble expres-
sion level of the fusion protein and the βgal signal. The
most likely explanation of this phenomenon is that the
βgal signal is not due to the fusion protein detected by
western blot but to some α-peptide released from the
fusion by the host proteases. This free α-peptide is pre-
sumably also much more efficient for βgal complementa-
tion than the fusion protein since it may penetrate the
tunnel present in M15 protein [36] at a much faster rate.
Unfused scFv characterization
The previous results were obtained with the scFv fused to
the α-peptide. Since it has been shown in several systems
that fusion to a partner may influence the fate of a protein
[37-40], we next examined the expression level of
scFv225.28S and its mutants as unfused proteins. After
cloning in plasmid pPM210, the scFv were expressed in
the Lon-deficient TG1 strain. The wild type scFv225.28S
was only detected in the soluble fraction (Fig. 8) and the
mutants were present in both the soluble and insoluble
fractions. All the mutant were expressed at a higher level
than the wild type scFv, but the increase in expression was
less pronounced than when the proteins were fused to the
α-peptide (Fig. 7). This was however mainly due to the
fact that the wild type scFv225.28S was expressed at a
higher level when not fused to the α-peptide because the
fusion was degraded by the host degradation machinery
as previously described for other βgal fusions [37].
We next compared the expression level of the best isolated
clone (scFv225.28S R4.1) in the periplasm and in the
cytoplasm. It must be noted that the two vectors used,
pPM210 and pAB1, are derived from the same pUC119
plasmid and that in both cases the scFv gene is under the
control of the lac promoter. The scFv expressed by the two
plasmids are exactly the same except for the pelB leader
peptide present at the N-terminal extremity of the scFv
expressed in the periplasm. After cleavage of this signal
sequence, the two scFv only differ by an additional N-ter-
minal Met-Ala dipeptide present in the scFv produced in
the cytoplasm.
As shown in Figure 9, the soluble expression level of
mutant R4.1 is higher both in the periplasm and in the
cytoplasm than that of the wild type scFv225.28S. In addi-
tion, the soluble cytoplasmic expression level of the
evolved R4.1 clone is higher than the wild type periplas-
mic expression level. This suggests that evolving scFv for
cytoplasmic expression is a valuable approach for increas-
ing the production of scFv in E. coli even if in this case it is
only a twofold increase much lower than in previously
reported cases [28].
In an attempt to increase further the cytoplasmic expres-
sion, the genes were cloned under the control of the
strong T7 promoter and expressed in strain
BL21(DE3)pLysS [41], which is naturally deficient in the
Lon protease [33,35]. As seen in Figure 10, the mutant
proteins were expressed at much higher levels than the
wild type. This is particularly the case for scFv225.28S
(Fig. 10B). To further characterize the mutant proteins,
soluble and insoluble protein fractions were prepared. As
shown in Figure 10, the increase in expression was due to
an increase in the insoluble fraction. In all cases, the
amount of soluble protein produced by the mutants was
comparable or even lower than that produced by the wild
type. This was true both for HuLys11 and 225.28S.
Discussion
In this report, we used the α-complementation assay as a
probe to detect soluble scFv expression in E. coli cyto-
plasm [21]. The system was used to evolve two scFv toMicrobial Cell Factories 2004, 3:16 http://www.microbialcellfactories.com/content/3/1/16
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increase their expression levels. After four rounds of
mutation and selection, we were able to select for scFv
fusions giving high βgal activity in vivo and in vitro.
Characterization of these mutant proteins showed that
they were expressed at higher levels in the cytoplasm than
the wild type scFv. The proteins were however quickly
degraded in the cell cytoplasm, and only a faint band was
detected in the soluble fraction and no protein at all in the
insoluble fraction (Fig. 7). This is not surprising for scFv
expressed in the reducing environment of the cytoplasm
since the lack of the two disulfide bonds results in only
marginally stable proteins quickly degraded by the host
proteases [42]. Since it has been shown that the Lon pro-
tease is involved in the degradation of many recombinant
proteins in E. coli [33], we expressed the scFv in an
isogenic strain deficient in this protease. Under those con-
ditions, the mutant scFv were expressed at a much higher
level than the wild type scFv. This was true for both scFv,
HuLys11 and 225.28S.
Cytoplasmic expression of unfused scFv Figure 8
Cytoplasmic expression of unfused scFv After cloning in plasmid pPM210, scFv225.28S and mutants were expressed in 
strain TG1lon. 5 µl of soluble and insoluble extracts were analyzed by Coomassie blue staining (A) and western blot (B) using 
the 9E10 anti-c-myc monoclonal antibody followed by an anti-mouse alkaline phosphatase-conjugated antibody and detected 
with the chromogenic substrate BCIP/NBT.Microbial Cell Factories 2004, 3:16 http://www.microbialcellfactories.com/content/3/1/16
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This increase in soluble cytoplamic production of the
scFv-α fusion was however not correlated with the βgal
activity (Fig. 7). For example, clone scFv225.28S R4.1 and
R4.2, which were expressed at a very different soluble level
(Fig. 7C), gave the same βgal signal (Fig. 5 &7E). This indi-
cates that most, if not all, of the βgal activity present in the
cell was not due to the scFv-α-peptide fusion but to some
free α-peptide released from the fusion by the host pro-
teases. This means that the α-complementation assay does
not sense the scFv-α expression level, as hypothesized, but
rather the amount of free α-peptide in the cell cytoplasm.
This could also explain why the system was not able to
detect differences between the clones in a lon background
(Fig. 7E).
Recently, Betton and collaborators [43] presented a model
of the possible in vivo competition between folding, aggre-
gation and degradation. Although this model was pre-
sented in the case of periplasmic proteins it might also
apply in the cytoplasm. The possible model and the
results for in vivo βgal complementation are shown in Fig-
ure 11. The "classical" competition between aggregation
and folding is represented by the green arrows at the top
of Figure 11. The scFv, emerging from the ribosome, will
fold into folding intermediates. A folding intermediate
may fold into a soluble native conformation, or may
misfold, leading to aggregation. Such a model has been
extensively studied in vivo and in vitro [44-47]. In this
model, an increase in α-complementation would result in
an increase in soluble protein expression and is the basis
of the tag-based systems to detect and evolve soluble pro-
teins [18]. As proposed by Betton and collaborators [43],
there is however a third pathway, leading to protein deg-
radation, in kinetic competition with aggregation. When
the proteins are expressed at a low level under the lac
promoter, most of the protein ends up as degraded
peptide fragments. However, since aggregation is a high
order kinetics, this is favored over degradation under the
high transcription rate due to the T7 promoter. This
would not be the case if degradation had not originated
from the same misfolded conformation as the aggregated
protein. However, since the soluble expression levels of
the scFv were higher in a lon strain, we must also admit
that there is a supplementary pathway involving the Lon
protease and leading from soluble fusion to degraded pro-
tein as suggested by Parsell and Sauer [42].
There is a striking difference between the properties of the
fused and the unfused scFv. Indeed, in the structural
context of the selection (as fusion to the α-peptide), all
the scFv, albeit highly sensitive to degradation, were
mainly expressed as soluble proteins. This is particularly
the case of HuLys11 for which no insoluble protein was
detected in Fig. 7G. As unfused scFv, all the clones were,
however, mainly found in the insoluble fraction,
particularly when expressed using the strong T7 promoter
(Fig. 10) but also when we used the same promoter than
during the selection process (Fig. 8). This shows that inter-
actions could take place between the scFv and the fused α-
peptide either during or after folding of the fusion pro-
Comparison of cytoplasmic and periplasmic soluble  expression Figure 9
Comparison of cytoplasmic and periplasmic soluble 
expression Genes of scFv225.28S and its mutant R4.1 were 
cloned in plasmid pAB1 [28]. In this plasmid, scFv genes are 
expressed under the control of the lac promoter with the 
pelB signal sequence fused at their N-terminal extremity in 
order to target protein to the periplasm. Soluble and insolu-
ble extracts were prepared from strain TG1 and were ana-
lyzed by Coomassie blue staining (A) and western blot (B) as 
in Figure 8. The two last extracts (Cyto) are those analyzed 
in lanes 1 and 2 of Figure 8 (soluble cytoplasmic extracts of 
scFv225.28S and R4.1, cloned in pPM210 and expressed in 
TG1lon).Microbial Cell Factories 2004, 3:16 http://www.microbialcellfactories.com/content/3/1/16
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tein. This may explain why all the mutations where local-
ized on the surface of HuLys11 (Fig. 6) since these
residues are more likely to take part in such an interaction.
This is particularly the case of the H46 mutation, which is
present in all three isolated mutants. In this case a
hydrophilic and charged residue (Glu) is replaced by an
hydrophobic Gly. As the α-peptide and the 30 aminoacid
peptide fused to the scFv contain some highly hydropho-
bic patches of residues (data not shown), this increase in
the hydrophobicity of the scFv surface may favor interac-
tion between the two partners that could enhance the sol-
ubility of the fusion by a chaperone-like effect, as
proposed for other fusions [48]. When the scFv is
expressed alone, without the C-terminal α peptide,
increasing the hydrophobicity of the surface residues
could result in an increase in aggregation [49], as noted in
our case (Fig. 8 &10).
Finally, another problem during the selection originated
in the presence of the 30 aminoacid peptide at the end of
the α-peptide. As we showed in the case of the model anti-
body scFv13, this peptide is needed to obtain good corre-
lation between protein soluble expression levels and in
vivo α-complementation since the introduction of a stop
codon at the end of the α-peptide resulted in a very strong
complementation with all the scFv, even the wild type
(clone 173S1 in Fig. 2 &3). This may explain why the
selection was biased towards degraded C-terminal α-pep-
tide. Indeed, Figure 3 shows that the role of the additional
30 aminoacid long C-terminal peptide is to decrease the
expression level of the fusion in order not to saturate the
detection system with the wild type scFv. This decrease in
the expression level is presumably accomplished through
targeting of the fusion to the cell degradation systems,
resulting in a rapid conversion of the fusion to free α-pep-
tide and in a bias in the selection procedure towards deg-
radation and thus aggregation. It must be noted that
Schwalbach and collaborators [50] recently selected a
mutant scFv using the GFP system, and that despite an
increase in GFP activity, they did not notice any increase
in soluble protein expression but rather an increase in
protein aggregation. They also noticed that protease
degradation of the fusion released free GFP in the cyto-
plasm, particularly when cells were induced for long peri-
Cytoplasmic expression under the T7 promoter Figure 10
Cytoplasmic expression under the T7 promoter SDS-PAGE of soluble and insoluble extracts (5 µl) of the best clones 
isolated after four rounds of mutagenesis, cloned in the pET23NN plasmid. Proteins were revealed either by Coomassie stain-
ing (top) or by western blot using the 9E10 anti-c-myc monoclonal antibody followed by an anti-mouse alkaline phosphatase-
conjugated antibody and detected with the chromogenic substrate BCIP/NBT. A) HuLys11 scFv and mutants; B) 225.28S scFv 
and mutants.Microbial Cell Factories 2004, 3:16 http://www.microbialcellfactories.com/content/3/1/16
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ods, that is, the conditions used during the selection
process. It should be noted that the authors used a lon+
strain for the selection instead of the E. coli B lon- strain
used by other authors [25,26,35]. These failures may be
due, in the specific case of cytoplasmic scFv expression, to
the lack of disulfide bond formation, leading to margin-
ally stable reduced scFv, quickly degraded by the cell pro-
teases [42].
Despite the difficulties associated with cytoplasmic scFv
expression, some scFv have been previously evolved for
folding under reducing conditions [28,51]. The systems
used relied on the binding activity of the scFv molecule,
avoiding the problem of protein degradation since
degraded antibody cannot bind to its antigen anymore. It
would thus be more appropriate to use yeast or bacterial
two-hybrid systems to evolve scFv [52,53]. The use of such
Schematic representation of the possible in vivo fates of scFv-α protein fusion Figure 11
Schematic representation of the possible in vivo fates of scFv-α protein fusion Schematic representation of folding, 
aggregation and degradation processes. In the scheme presented, the newly translated protein (left) is assumed to proceed 
through two alternative pathways: either it folds to give the folded protein (soluble native) or it evolves via a side reaction lead-
ing to a misfolded protein (misfolding). A second kinetic competition is thought to occur between degradation and aggregation 
of the misfolded protein. Green arrows represent the kinetic competition between folding and aggregation [44] on which the 
soluble reporter assays are based [18]. Red arrows represent an additional pathway leading to degradation [43] and release of 
free α-peptide in the cytoplasm.Microbial Cell Factories 2004, 3:16 http://www.microbialcellfactories.com/content/3/1/16
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systems could also avoid the selection of mutations that
modify or abolish the antigen-binding properties of the
scFv as is presumably the case in our selection since sev-
eral of the mutations are located in the CDR loops of the
antibody fragments (see additional files 4 and 2,
HuLys11aa.txt and 22528Saa.txt). Another possibility
could be to use E. coli protease-deficient strains to limit
protein degradation during the selection, but the results
shown in Fig. 7E demonstrate that even in such a strain
there is no correlation between the soluble expression
level and the βgal activity present in the cell.
Conclusions
In this report, we used the α-complementation assay as a
probe to detect soluble scFv expression in E. coli cyto-
plasm. The system was used to evolve two scFv in order to
increase their expression levels. After four rounds of muta-
tion and selection, we were able to select for scFv fusion
giving a high βgal activity in vivo and in vitro.
Characterization of these mutant proteins showed that
their expression levels were much higher in the cytoplasm
than those of the wild type scFv, particularly in a Lon-defi-
cient strain. There was however no correlation between
the  βgal activity present in the cell and the soluble
expression level of the scFv, showing that the βgal signal
is presumably due to some free α-peptide released from
the fusion protein by the host proteases and not to the
non-degraded soluble scFv-α fusion.
Methods
Media, plasmids and bacterial strains
MacConkey agar, M9 and LB media were previously
described [30]. Strain TG1 is E. coli K-12, [F' traD36 lacIq
∆(lacZ)M15  proA+B+]  supE44  ∆(hsdM-mcrB)5  thi  ∆(lac-
proAB). CAG626F' is E. coli K-12, [F' lacIq∆(lacZ)M15
zzf::mini-Tn10(KanR)proA+B+]  lacZ(am)  pho(am)  lon
trp(am) tyrT [supC(ts)] rpsL mal(am) [54].
TG1lon strain was constructed by P1 transduction. First,
zaj-3054::Tn10, located at 9.95 minutes, was inserted near
to the lon gene in strain CAG626F' by P1 transduction
from CAG12017 [55]. In a second step, lon  and  zaj-
3054::Tn10 were co-transduced in TG1 using P1 phage.
The introduction of the lon mutation was verified by com-
paring the resistance to UV irradiation and to nitrofuran-
toin of TG1 and TG1lon.
Plasmid pPM170 for the cytoplasmic expression of scFv
fused to the α-fragment of βgal was constructed as follows
(Fig. 1). A fragment containing a Shine Dalgarno
sequence followed by a NcoI site containing the ATG ini-
tiator was obtained by PCR amplification of pPM160 [28]
with pTrpFOR (CGGGAATAAGCTTCAACGCCAG) and
EcoAlpha.for (GTGAATGAATTCGAATGGTGATGATGG)
primers. The underlined sequence corresponds to an
EcoRI site designed in order to get in frame fusion of the
scFv with the α-fragment of βgal present in pUC119 when
the fragment was cloned in the EcoRI site of pUC119. The
amplified fragment also contained an HpaI site located 34
bp upstream from the ATG initiator of the scFv gene. This
PCR band was digested with HpaI and EcoRI enzymes and
ligated with HincII-EcoRI-digested pUC119 plasmid, lead-
ing to the pPM170 plasmid.
Plasmid pAB1 for the periplasmic expression of scFv
under the lac  promoter has been described previously
[28]. Plasmid pPM210 is identical to pPM170 except for
the presence of a stop codon between the scFv and the α-
fragment of βgal. It was obtained by cloning the NcoI-
EcoRI fragment of pAB1 in the NcoI and EcoRI sites of
pPM170. scFv cloned in pPM210 were transcribed from a
lac promoter and tagged at their C-terminal extremity by
both a c-myc and a polyhistidine flags.
Plasmid pET23NN was designed to easily clone NcoI-NotI
fragment containing scFv from pPM170-derived plasmids
under the T7 promoter with C-terminal c-myc and His6
tags. pET23d(+) obtained from Novagen was first digested
with XhoI enzyme, filled-in with T4 DNA polymerase then
digested with NcoI. This fragment was ligated with a NcoI-
EcoRI(filled) fragment excised from the pAB1 plasmid
[28]. The resulting plasmid contained a T7 promoter, fol-
lowed by a NcoI site containing the ATG initiator, a NotI
site followed by a c-myc and a His6 tag [same sequence as
pPM170 (Fig. 1) but with a stop codon before the EcoRI
site]. Due to the removal of a T, presumably during T4
DNA polymerase treatment, ligation between the filled
EcoRI and XhoI sites reconstituted the EcoRI site (GAATTC-
GAG instead of GAATTTCGAG).
Error-prone mutagenesis
The conditions used are those described to obtain 0.2%
mutations with p(AT->NN) = p(GC->NN) and p(AT-
>GC) = p(AT->TA) for ten duplications [28,56]. The
amplified band was digested with NcoI and NotI and
cloned in pPM170. The ligation was transformed in TG1
by electroporation. Bacteria were plated on MacConkey
lactose and M9 lactose agar plates supplemented with 100
µg ml-1 ampicillin, 1 mM isopropyl-β-D-thiogalactopyra-
noside (IPTG) and 1 µg ml-1 of vitamin B1 in the case of
the M9 plates.
Preparation of bacterial extracts
Expression under the T7 promoter was conducted essen-
tially as described except that LB was used instead of
M9ZB [41]. Freshly transformed cells were grown in LB
supplemented with 100 µg ml-1 ampicillin and 20 µg ml-1
chloramphenicol until an OD600 of about 1 and kept at
4°C overnight. In the morning, the cells were diluted toMicrobial Cell Factories 2004, 3:16 http://www.microbialcellfactories.com/content/3/1/16
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an OD600 of 0.1 in the same medium and incubated with
shaking for 2 hours at 37°C, then 0.4 mM IPTG was
added and the culture continued for 3 hours at 30°C. The
cultures were cooled down on ice for 5 to 30 minutes,
then centrifuged and resuspended at a concentration of 40
OD600 in 50 mM Tris-HCl (pH 8.0), 2 mM EDTA. Cells
were lysed by freezing/thawing followed by a brief sonica-
tion. The insoluble fraction was collected by centrifuga-
tion (30 minutes at 17 500 g), washed once, then
resuspended in the same volume of buffer.
For expression under the lactose promoter (plasmid
pPM170), an overnight culture in LB supplemented with
100 µg ml-1 ampicillin and 1% glucose was diluted to a
final OD600 of 0.1 in LB supplemented with 100 µg ml-1
ampicillin and incubated with shaking for 2 hours at
37°C, then 1 mM IPTG was added and the culture contin-
ued for 3 hours at 30°C. Cytoplasmic soluble extracts
were prepared as follows. 16 OD of culture were cooled
down on ice for 5 to 30 minutes, then centrifuged and
resuspended in 400 µl of 20 mM Tris-HCl (pH 8.0), 0.7 M
sucrose. Hen egg-white lysozyme at a 0.1 mg ml-1 concen-
tration was added and the extract incubated 2 minutes on
ice. 800 µl of a cold solution of 1.5 mM EDTA were added
slowly within ten minutes. Extract were kept 30 minutes
on ice then sonicated 20 s. The insoluble fraction was col-
lected by centrifugation (30 minutes at 17 500 g), washed
once, then resuspended in the same volume of buffer than
the soluble fraction (1.2 ml).
Measurement of βgal activity
Cells were grown under the same conditions as those
described in "Preparation of bacterial extracts" for the lac-
tose promoter. Five hundred µl of cells were lysed using
SDS/chloroform and βgal activity determined and
expressed as described in Miller [30]. For Figure 5 and 7,
we also prepared soluble extracts using the protocol
described in "Preparation of bacterial extracts" and βgal
activity was determined as above.
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